Press release
Globally, More than 100+ Key Companies are Developing Therapies for Ovarian Cancer to Improve the Treatment Scenario
Ovarian cancer Pipeline
"Ovarian Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ovarian Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Ovarian Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Ovarian Cancer Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.
Ovarian Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ovarian Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Ovarian Cancer Therapeutics Analysis
Globally, more than 100+ key companies are developing therapies for Ovarian Cancer. The companies with Ovarian Cancer drug candidates in the most advanced stage, i.e., phase III, include Genentech.
Some of the key companies actively working in the Ovarian Cancer Therapeutics Market include Genentech, Genmab, AstraZeneca, BioNumerik Pharmaceuticals, On Target Laboratories, Gilead Sciences, Acerta Pharma, MedImmune, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, AB Science, Syndax Pharmaceuticals, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Clovis Oncology, CSPC ZhongQi Pharmaceutical, Immunitor LLC, Ellipses Pharma, Impact Therapeutics, Inc., Eli Lilly and Company, BeiGene, Hoffmann-La Roche, Apexigen, Novartis Oncology, Plexxikon, Jiangxi Qingfeng Pharmaceutical Co. Ltd., PharmaMar, Aprea Therapeutics, VBL Therapeutics, Tesaro, Cristal Therapeutics, Bayer, Pfizer, Hrain Biotechnology Co., Ltd., Regeneron Pharmaceuticals, DCPrime BV, PTC Therapeutics, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Arcus Biosciences, Verastem, Inc., Celsion, and others.
Ovarian Cancer Therapies covered in the report include:
Atezolizumab (Genentech)
Tisotumab Vedotin (Genmab)
Pembrolizumab (Merck)
And Several Other.
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Ovarian Cancer Current Treatment Patterns
4. Ovarian Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ovarian Cancer Late Stage Products (Phase-III)
7. Ovarian Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ovarian Cancer Discontinued Products
13. Ovarian Cancer Product Profiles
14. Ovarian Cancer Key Companies
15. Ovarian Cancer Key Products
16. Dormant and Discontinued Products
17. Ovarian Cancer Unmet Needs
18. Ovarian Cancer Future Perspectives
19. Ovarian Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Globally, More than 100+ Key Companies are Developing Therapies for Ovarian Cancer to Improve the Treatment Scenario here
News-ID: 2682946 • Views: …
More Releases from DelveInsight Business Research
Global Patient Engagement Solutions Market to reach USD 59,499.28 million by 203 …
According to DelveInsight's analysis, The growth of the patient engagement solutions market is primarily fueled by several major factors, including the increasing burden of chronic conditions such as diabetes and cardiovascular diseases, which require continuous patient involvement and monitoring. The industry is further propelled by the move toward patient-centric healthcare models, ongoing technological innovations, and the introduction of new digital tools and platforms. Moreover, supportive government policies and initiatives aimed…
Global Magnetic Resonance Imaging Devices Market to reach USD 13,553.33 million …
According to DelveInsight's analysis, The growing incidence of chronic illnesses-including heart disease, cancer, and neurological disorders is driving demand for advanced diagnostic methods such as MRI, which provides highly detailed imaging of soft tissues and internal organs. Increasing awareness and a stronger focus on early disease detection are also prompting both patients and healthcare professionals to rely on MRI for faster and more accurate diagnosis. In addition, ongoing technological progress…
Global Microbial Fermentation Technology Market Size was USD 33,956.10 million i …
According to DelveInsight's analysis, The microbial fermentation technology market is experiencing strong growth, largely due to the increasing incidence of chronic illnesses such as cancer and a range of infectious diseases, including HIV, hepatitis B and C, and influenza. The market is also being boosted by the rising need for advanced therapeutic products like cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies. Moreover, progress in synthetic biology and precision…
Global Surgical Robotic System Market to reach USD 29,785.13 million by 2032 at …
According to DelveInsight's analysis, The growing prevalence of chronic illnesses such as cancer, cardiovascular diseases, and orthopedic disorders is driving demand for advanced surgical solutions, which in turn is accelerating the expansion of the surgical robotic systems market. Since many of these conditions require complex, highly precise procedures, robotic-assisted surgery is becoming a preferred option due to its superior precision, less invasive nature, and faster patient recovery. At the same…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
